Jaguar Health
Jaguar Health is a pharmaceutical company focused on developing and commercializing plant-based medicines for gastrointestinal (GI) diseases in humans and animals. Its primary product, Mytesi, is a first-in-class anti-secretory agent approved for managing HIV/AIDS-related diarrhea. Jaguar Health operates through two segments: Human Health, which generates most of its revenue, and Animal Health. The company's pipeline includes products like crofelemer for cancer therapy-related diarrhea and short bowel syndrome, as well as animal health products such as Canalevia for chemotherapy-induced diarrhea in dogs. Headquartered in San Francisco, California, Jaguar Health aims to address urgent global health needs with its plant-based prescription medicines.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Napo Pharmaceuticals
Venture Round in 2023
Napo Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of proprietary pharmaceuticals for international markets. Founded in 2001 and headquartered in San Francisco, California, with a subsidiary in Mumbai, India, the company specializes in treatments for gastrointestinal conditions. Napo's main product, Crofelemer, is designed to provide symptomatic relief from noninfectious diarrhea in adult patients living with HIV/AIDS, particularly those undergoing antiretroviral therapy. In addition to Crofelemer, Napo Pharmaceuticals offers a range of products targeting various gastrointestinal indications, including NP-500 for insulin-resistant diseases, CRO-IBS for diarrhea-predominant irritable bowel syndrome, CRO-HIV for AIDS-related diarrhea, CRO-ID for acute infectious diarrhea, and CRO-PED for pediatric diarrhea. The company's mission is to meet the needs of patients in high-margin Western markets while addressing critical health issues associated with gastrointestinal disorders.
Napo Pharmaceuticals
Acquisition in 2017
Napo Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of proprietary pharmaceuticals for international markets. Founded in 2001 and headquartered in San Francisco, California, with a subsidiary in Mumbai, India, the company specializes in treatments for gastrointestinal conditions. Napo's main product, Crofelemer, is designed to provide symptomatic relief from noninfectious diarrhea in adult patients living with HIV/AIDS, particularly those undergoing antiretroviral therapy. In addition to Crofelemer, Napo Pharmaceuticals offers a range of products targeting various gastrointestinal indications, including NP-500 for insulin-resistant diseases, CRO-IBS for diarrhea-predominant irritable bowel syndrome, CRO-HIV for AIDS-related diarrhea, CRO-ID for acute infectious diarrhea, and CRO-PED for pediatric diarrhea. The company's mission is to meet the needs of patients in high-margin Western markets while addressing critical health issues associated with gastrointestinal disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.